Table 1.
Characteristics of the Subjects for Proteomics
| GOLD Stage | Lung Cancer | Sex | Age (yr) (Mean) | FEV1 (L) (Mean) | FEV1pp (Mean) |
|---|---|---|---|---|---|
| 0/1 | Yes | 3F/6M | 52–83 (71.0) | 1.7–4.5 (2.9) | 84–133 (102.8) |
| 0/1 | No | 2F/7M | 44–68 (61.2) | 2.0–4.9 (3.4) | 83–180 (106.5) |
| 2 | Yes | 3F/7M | 48–84 (72.2) | 0.9–2.9 (1.7) | 51–73 (62.0) |
| 2 | No | 6F/4M | 43–79 (61.7) | 1.5–2.2 (1.8) | 52–76 (66.5) |
| 3/4 | Yes | 6F/4M | 53–82 (67.7) | 0.5–1.5 (1.0) | 19–47 (37.8) |
| 3/4 | No | 2F/8M | 47–64 (56.3) | 0.4–0.8 (0.6) | 10–22 (15.9) |
Definition of abbreviations: FEV1pp = FEV1 percent of the predicted value; GOLD = Global Initiative for Obstructive Lung Disease.